A Phase I open-label, multi-center study of BGB-A317 evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-A317 in Chinese patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs BGB A317 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Aug 2017 According to a BeiGene media release, the company expected data from this study in 2017.
- 30 Dec 2016 According to a BeiGene media release, first patient has been dosed in this trial. Professor Yilong Wu from Guangdong General Hospital is the lead principal investigator of the study.
- 30 Dec 2016 Status changed from not yet recruiting to recruiting, as reported by a BeiGene media release.